These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 38851389)

  • 1. Recommendations for Tumor Mutational Burden Assay Validation and Reporting: A Joint Consensus Recommendation of the Association for Molecular Pathology, College of American Pathologists, and Society for Immunotherapy of Cancer.
    Furtado LV; Bifulco C; Dolderer D; Hsiao SJ; Kipp BR; Lindeman NI; Ritterhouse LL; Temple-Smolkin RL; Zehir A; Nowak JA
    J Mol Diagn; 2024 Aug; 26(8):653-668. PubMed ID: 38851389
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach.
    Luchini C; Bibeau F; Ligtenberg MJL; Singh N; Nottegar A; Bosse T; Miller R; Riaz N; Douillard JY; Andre F; Scarpa A
    Ann Oncol; 2019 Aug; 30(8):1232-1243. PubMed ID: 31056702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor mutational burden standardization initiatives: Recommendations for consistent tumor mutational burden assessment in clinical samples to guide immunotherapy treatment decisions.
    Stenzinger A; Allen JD; Maas J; Stewart MD; Merino DM; Wempe MM; Dietel M
    Genes Chromosomes Cancer; 2019 Aug; 58(8):578-588. PubMed ID: 30664300
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recommendations for Cell-Free DNA Assay Validations: A Joint Consensus Recommendation of the Association for Molecular Pathology and College of American Pathologists.
    Lockwood CM; Borsu L; Cankovic M; Earle JSL; Gocke CD; Hameed M; Jordan D; Lopategui JR; Pullambhatla M; Reuther J; Rumilla KM; Tafe LJ; Temple-Smolkin RL; Terraf P; Tsimberidou AM
    J Mol Diagn; 2023 Dec; 25(12):876-897. PubMed ID: 37806433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists.
    Li MM; Datto M; Duncavage EJ; Kulkarni S; Lindeman NI; Roy S; Tsimberidou AM; Vnencak-Jones CL; Wolff DJ; Younes A; Nikiforova MN
    J Mol Diagn; 2017 Jan; 19(1):4-23. PubMed ID: 27993330
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of high tumor mutational burden in solid tumors and challenges for biomarker application.
    McNamara MG; Jacobs T; Lamarca A; Hubner RA; Valle JW; Amir E
    Cancer Treat Rev; 2020 Sep; 89():102084. PubMed ID: 32738738
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Harmonizing tumor mutational burden analysis: Insights from a multicenter study using in silico reference data sets in clinical whole-exome sequencing (WES).
    Yu L; Zhang Y; Wang D; Li L; Zhang R; Li J
    Am J Clin Pathol; 2024 Oct; 162(4):408-419. PubMed ID: 38733635
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Programmed Death Ligand-1 and Tumor Mutation Burden Testing of Patients With Lung Cancer for Selection of Immune Checkpoint Inhibitor Therapies: Guideline From the College of American Pathologists, Association for Molecular Pathology, International Association for the Study of Lung Cancer, Pulmonary Pathology Society, and LUNGevity Foundation.
    Sholl LM; Awad M; Basu Roy U; Beasley MB; Cartun RW; Hwang DM; Kalemkerian G; Lopez-Rios F; Mino-Kenudson M; Paintal A; Reid K; Ritterhouse L; Souter LA; Swanson PE; Ventura CB; Furtado LV
    Arch Pathol Lab Med; 2024 Jul; 148(7):757-774. PubMed ID: 38625026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology.
    Sepulveda AR; Hamilton SR; Allegra CJ; Grody W; Cushman-Vokoun AM; Funkhouser WK; Kopetz SE; Lieu C; Lindor NM; Minsky BD; Monzon FA; Sargent DJ; Singh VM; Willis J; Clark J; Colasacco C; Bryan Rumble R; Temple-Smolkin R; B Ventura C; Nowak JA
    Arch Pathol Lab Med; 2017 May; 141(5):625-657. PubMed ID: 28165284
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor mutational burden assessed by targeted NGS predicts clinical benefit from immune checkpoint inhibitors in non-small cell lung cancer.
    Alborelli I; Leonards K; Rothschild SI; Leuenberger LP; Savic Prince S; Mertz KD; Poechtrager S; Buess M; Zippelius A; Läubli H; Haegele J; Tolnay M; Bubendorf L; Quagliata L; Jermann P
    J Pathol; 2020 Jan; 250(1):19-29. PubMed ID: 31471895
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Japanese Society of Medical Oncology/Japan Society of Clinical Oncology/Japanese Society of Pediatric Hematology/Oncology-led clinical recommendations on the diagnosis and use of immunotherapy in patients with high tumor mutational burden tumors.
    Mishima S; Naito Y; Akagi K; Hayashi N; Hirasawa A; Hishiki T; Igarashi A; Ikeda M; Kadowaki S; Kajiyama H; Kato M; Kenmotsu H; Kodera Y; Komine K; Koyama T; Maeda O; Miyachi M; Nishihara H; Nishiyama H; Ohga S; Okamoto W; Oki E; Ono S; Sanada M; Sekine I; Takano T; Tao K; Terashima K; Tsuchihara K; Yatabe Y; Yoshino T; Baba E
    Int J Clin Oncol; 2023 Aug; 28(8):941-955. PubMed ID: 37300720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology.
    Bartley AN; Washington MK; Ventura CB; Ismaila N; Colasacco C; Benson AB; Carrato A; Gulley ML; Jain D; Kakar S; Mackay HJ; Streutker C; Tang L; Troxell M; Ajani JA
    Arch Pathol Lab Med; 2016 Dec; 140(12):1345-1363. PubMed ID: 27841667
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Guidelines for Validation of Next-Generation Sequencing-Based Oncology Panels: A Joint Consensus Recommendation of the Association for Molecular Pathology and College of American Pathologists.
    Jennings LJ; Arcila ME; Corless C; Kamel-Reid S; Lubin IM; Pfeifer J; Temple-Smolkin RL; Voelkerding KV; Nikiforova MN
    J Mol Diagn; 2017 May; 19(3):341-365. PubMed ID: 28341590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of commonly used solid tumor targeted gene sequencing panels for estimating tumor mutation burden shows analytical and prognostic concordance within the cancer genome atlas cohort.
    Bevins N; Sun S; Gaieb Z; Thorson JA; Murray SS
    J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32217764
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Validation of a Targeted Next-Generation Sequencing Panel for Tumor Mutation Burden Analysis: Results from the Onconetwork Immuno-Oncology Consortium.
    Fenizia F; Alborelli I; Costa JL; Vollbrecht C; Bellosillo B; Dinjens W; Endris V; Heydt C; Leonards K; Merkelback-Bruse S; Pfarr N; van Marion R; Allen C; Chaudhary R; Gottimukkala R; Hyland F; Wong-Ho E; Jermann P; Machado JC; Hummel M; Stenzinger A; Normanno N
    J Mol Diagn; 2021 Jul; 23(7):882-893. PubMed ID: 33964449
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and the American Society of Clinical Oncology.
    Sepulveda AR; Hamilton SR; Allegra CJ; Grody W; Cushman-Vokoun AM; Funkhouser WK; Kopetz SE; Lieu C; Lindor NM; Minsky BD; Monzon FA; Sargent DJ; Singh VM; Willis J; Clark J; Colasacco C; Rumble RB; Temple-Smolkin R; Ventura CB; Nowak JA
    J Clin Oncol; 2017 May; 35(13):1453-1486. PubMed ID: 28165299
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic.
    Chan TA; Yarchoan M; Jaffee E; Swanton C; Quezada SA; Stenzinger A; Peters S
    Ann Oncol; 2019 Jan; 30(1):44-56. PubMed ID: 30395155
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor mutational burden assessment in non-small-cell lung cancer samples: results from the TMB
    Ramos-Paradas J; Hernández-Prieto S; Lora D; Sanchez E; Rosado A; Caniego-Casas T; Carrizo N; Enguita AB; Muñoz-Jimenez MT; Rodriguez B; Perez-Gonzalez U; Gómez-Sánchez D; Ferrer I; Ponce Aix S; Nuñez Buiza Á; Garrido P; Palacios J; Lopez-Rios F; Garrido-Martin EM; Paz-Ares L
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33963008
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pan-cancer analysis of heterogeneity of tumor mutational burden and genomic mutation under treatment pressure.
    Huang RJ; Huang YS; An N; Hu JJ; Wu CY; Chen YX; Chen JY; Zhao Q; Xu RH; Yuan SQ; Wang F
    ESMO Open; 2024 Jul; 9(7):103494. PubMed ID: 38981309
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Choosing tumor mutational burden wisely for immunotherapy: A hard road to explore.
    Li R; Han D; Shi J; Han Y; Tan P; Zhang R; Li J
    Biochim Biophys Acta Rev Cancer; 2020 Dec; 1874(2):188420. PubMed ID: 32828886
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.